Journal for ImmunoTherapy of Cancer (Nov 2021)
720 CUE-102 selectively activates and expands WT1-specific T cells for the treatment of patients with WT1+ malignancies
- Jason Brown,
- Saso Cemerski,
- Alex Histed,
- Natasha Girgis,
- Zohra Merazga,
- Fulvio Diaz,
- Fan Zhao,
- Anish Suri,
- Kenneth Pienta,
- John Ross,
- Matteo Levisetti,
- Raymond Moniz,
- Steve Quayle,
- Christie Zhang,
- Steven Hatfield,
- Kristin Yeung,
- Mark Haydock,
- Luke Witt,
- Wynona Bautista
Affiliations
- Jason Brown
- 2Sosei Heptares
- Saso Cemerski
- Aff1 grid.417993.10000000122600793Merck Research Laboratories Boston MA USA
- Alex Histed
- 1CUE Biopharma, Cambridge, MA, USA
- Natasha Girgis
- 1CUE Biopharma, Cambridge, MA, USA
- Zohra Merazga
- 1CUE Biopharma, Cambridge, MA, USA
- Fulvio Diaz
- 1CUE Biopharma, Cambridge, MA, USA
- Fan Zhao
- 1CUE Biopharma, Cambridge, MA, USA
- Anish Suri
- 1CUE Biopharma, Cambridge, MA, USA
- Kenneth Pienta
- 2Johns Hopkins University School of Medic, Baltimore, MD, USA
- John Ross
- Emergency Department, Northwick Park Hospital, London North West University Healthcare NHS Trust, Harrow, UK
- Matteo Levisetti
- 15Cue Biopharma Inc, Cambridge, MA, USA
- Raymond Moniz
- 15Cue Biopharma Inc, Cambridge, MA, USA
- Steve Quayle
- 15Cue Biopharma Inc, Cambridge, MA, USA
- Christie Zhang
- 1Cue Biopharma, Cambridge, MA, United States
- Steven Hatfield
- 1Cue Biopharma, Cambridge, MA, United States
- Kristin Yeung
- 1Cue Biopharma, Cambridge, MA, United States
- Mark Haydock
- 1Cue Biopharma, Cambridge, MA, United States
- Luke Witt
- 1Cue Biopharma, Cambridge, MA, United States
- Wynona Bautista
- 1Cue Biopharma, Cambridge, MA, United States
- DOI
- https://doi.org/10.1136/jitc-2021-SITC2021.720
- Journal volume & issue
-
Vol. 9,
no. Suppl 2
Abstract
No abstracts available.
